



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/735,910	
			Filing Date	December 16, 2003	
			First Named Inventor	Ru Chih HUANG et al.	
			Art Unit	1616-1614	
			Examiner Name	L. Royds	
Sheet	1	of	1	Attorney Docket Number	2240-199065

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
LAZ	AA	4,708,964	11/24/1987	Allen	


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA		
	CB		
	CC		
	CD		
	CE		
	CF		
	CG		
	CH		
	CI		
	CJ		
	CK		
	CL		
	CM		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	02 NOVEMBER 2006
-----------------------	---	--------------------	------------------



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete If Known 10/735.910

Application Number	Continuation of Appl. 10/270,313
--------------------	---

Filing Date	December 16, 2003
-------------	-------------------

First Named Inventor	Ru Chih C. HUANG et al.
----------------------	-------------------------

Group Art Unit	1614
----------------	------

Examiner Name	Mr. James H. Reamer L. A. RIND
---------------	---

Attorney Docket Number	2240-199065
------------------------	-------------

sU.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
LAR	1	6,365,787		Huang et al.	04/2002	
LAR	2	5,663,209		Huang et al.	09/1997	
LAR	3	6,291,524		Huang et al.	09/2001	
LAR	4	6,214,874		Huang et al.	04/2001	
LAR	5	4,774,229		Jordan	09/1988	
LAR	6	5,276,060		Neiss et al.	01/1994	
LAR	7	6,071,949		Mulshine et al.	06/2000	
LAR	8	4,425,327		Moller et al.	01/1984	
LAR	9	4,880,637		Jordan	11/1989	
LAR	10	5,008,294		Neiss et al.	04/1991	
LAR	11	5,559,149		Clum et al.	09/1996	
LAR	12	5,827,898		Khandwala et al.	10/1998	
LAR	13	5,837,252		Sinnott et al.	11/1998	
LAR	14	5,965,616		Wang et al.	10/1999	
LAR	15	6,165,788		Bennett et al.	12/2000	
LAR	16	6,245,523		Altieri	01/2001	

[illegible]

**Examiner
Signature**

Date
Considered

02 NOVEMBER 2006.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ☐

PTO/SB/08A (08-00)

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Complete if Known 10/135910

Application Number	Continuation of Appl. 10/270,313
Filing Date	December 16, 2003
First Named Inventor	Ru Chih C. HUANG et al.
Group Art Unit	1614
Examiner Name	Mr. James H. Reamer L.A. ROYDS
Attorney Docket Number	2240-199065

(use as many sheets as necessary)

Sheet	2	Of	2
-------	---	----	---

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	17	Russell et al., "Neoplasm inhibitors comprising metal salts and phenol derivatives"; CA: 111(3)17704R PATENT ABSTRACT	
	18	Rao et al., "Regioselective cleavage of the methylenedioxy group: conversion of (-)-austrobaillignan-5 to (-)-dihydroguaiaretic acid"; CA: 112(23)118499d JOURNAL ABSTRACT	
	19	Giza et al., "A self-inducing runaway—replication plasmid expression system utilizing the ROP protein," Gene 78:73-84 (1989).	
LAR	20	Gnabre et al., "Isolation of anti-HIV-1 lignans from <i>Larrea tridentata</i> counter-current chromatography," J. Chromatography A, 719: 353-364 (1995).	
	21	C.W. Perry et al., "Synthesis of Lignans. I. Nordihydroguaiaretic Acid"; J. Org. Chem. 37(26): 4371-4376 (1972).	
	22	Staal et al., "Antioxidants inhibit stimulation of HIV transcription," AIDS Research and Human Retroviruses, 9(4): 299-306 (1993).	
	23	Weislow et al., "New soluble-formazan assay for HIV-1 cytopathic effects: Application to high-flux screening of synthetic and natural products for AIDS—Antiviral activity," J. National Cancer Inst. 81(1): 577-586 (1989).	
	24	Russell, "Compositions containing catecholic butanes and zinc for treating solid tumors"; CA: 110(12)101816r PATENT ABSTRACT	
LAR	25	Chen et al., Antiviral Activities of Methylated Nordihydroguaiaretic Acids 2. Targeting Herpes Simplex Virus Replication by Mutation Insensitive Transcription Inhibitor Tetra-O-methyl-NDGA, Journal of Medicinal Chemistry, 1998, Vol. 41, No. 16, pp.301-3007	
LAR	26	Gnabre et al., Characterization of Anti-HIV Lignans from <i>Larrea tridentata</i> , Tetrahedron 1995, Vol. 51, No. 45, pp. 12203-12210	
LAR	27	Gnabre et al., Inhibition of Human Immunodeficiency Virus Type 1 Transcription and Replication by DNA Sequence-S-elective Plant Lignans, Proc. Natl. Acad. Sci., USA, 1995, Vol. 92, pp. 11239-11243	
LAR	28	Gisvold et al., Lignans from <i>Larrea Divaricata</i> , Journal of Pharmaceutical Sciences, 1994, Vol. 63, No. 12, pp. 1905-1907	
LAR	29	Hwu et al, Antiviral Activities of Methylated Nordihydroguaiaretic Acids. 1. Synthesis Structure Identification and Inhibition of Tat-Regulated HIV Transactivation J. Med. Chem., 1998, Vol. 41, No. 16, pp. 2994-3000	
LAR	30	Huang et al., Regulation of HIV Promotor Activities In Human Embryonal Carcinoma Cells, NTERA-2, Gene Regulation and AIDS, 1989, pp. 147-160	
LAR	31	Li et al., Transcriptional Analysis of Human Survivin Gene Expression, Biochem. J. (1999), 344 pp. 305-311.	
LAR	32	Connor et al., Regulation of Apoptosis Cell Division by p34cdc2 Phosphorylation of Survivin, PNAS, Nov. 21, 2000, Vol. 27, No. 24, pp. 13101-13107	
LAR	33	Li et al., The Cancer Antiapoptosis Mouse Survivin Gene: Characterization of Locus and Transcriptional Requirements of Basal and Cell Cycle-Dependent Expression, Cancer Research 59, July 1, 1999, pp. 3134-3151	
Examiner Signature	[Signature]		Date Considered
			02 NOVEMBER 2004

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.